Worldwide Innovative Networking Consortium

On the heels of the WINTHER study, the consortium has planned a new trial called MERCURY, and will launch a blood and tissue repository.

The NCI will launch a lab network to provide researchers with centralized assays for conducting genomic and pharmacodynamic analysis for molecularly targeted drugs.

While the company reported an increase in revenues from biopharma partners, this gain was more than offset by lower consumable sales.

Illumina is the latest to join the consortium, which is focused on personalizing cancer care.

The algorithm may be able to rationally determine the three-drug strategy with the best chance of overcoming resistance and improving survival in advanced lung cancer patients.

Launched by the Institute Gustav Roussy in France and the University of Texas MD Anderson Cancer Center, the Worldwide Innovative Networking Consortium aims to help drugmakers change the way they develop drugs by focusing on treating diseases with common molecular features, rather than treating disease at an organ site.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

In Science this week: reduction in bee phylogenetic diversity, and more.